News
VYNE
2.422
-1.94%
-0.048
Weekly Report: what happened at VYNE last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at VYNE last week (0408-0412)?
Weekly Report · 04/15 11:11
Weekly Report: what happened at VYNE last week (0401-0405)?
Weekly Report · 04/08 11:16
Weekly Report: what happened at VYNE last week (0325-0329)?
Weekly Report · 04/01 11:14
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. Sunshine Biopharma stock moved upwards by 39.5% as the company's market cap rose to $8.3 million. Xilio Therapeutics and Medpace Hldgs also rose in the wake of Q4 earnings.
Benzinga · 03/29 20:30
Weekly Report: what happened at VYNE last week (0318-0322)?
Weekly Report · 03/25 11:17
Weekly Report: what happened at VYNE last week (0311-0315)?
Weekly Report · 03/18 11:15
Weekly Report: what happened at VYNE last week (0304-0308)?
Weekly Report · 03/11 11:12
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
NASDAQ · 03/08 17:00
Weekly Report: what happened at VYNE last week (0226-0301)?
Weekly Report · 03/04 11:14
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
Vyne Therapeutics Inc. Faces long-term business risks stemming from climate change. The company has disclosed a new risk in the Natural and Human Disruptions category. Wall Street has a Moderate Buy consensus rating on Vyne stock based on 2 Buys.
TipRanks · 03/03 06:01
Vyne Therapeutics files for $250M mixed shelf
Healthcare Vyne Therapeutics files for $250M mixed shelf to raise $250 million. SEC filing says company plans to offer and sell common stock, preferred stock, and warrants to raise the money. The company is a subsidiary of Vyne Pharmaceuticals Inc.
Seeking Alpha · 03/01 22:40
Catalyst Watch: Jobs report, Powell treks to Congress, Target earnings and major tech conference
Seeking Alpha · 03/01 20:00
Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments
TipRanks · 02/29 20:25
Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.
Dow Jones · 02/29 20:16
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
Benzinga · 02/29 20:06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)
TipRanks · 02/29 16:01
Recap: VYNE Therapeutics Q4 Earnings
VYNE Therapeutics reported its Q4 earnings on February 29, 2024. The company beat estimates by 64.0% and is expected to report earnings of $-0.18. Last quarter the company beat on EPS by $0.22 and the share price rose 3.0%.
Benzinga · 02/29 13:30
BRIEF-VYNE Therapeutics FY Adjusted Net Income USD -25.147 Million
Reuters · 02/29 13:00
VYNE Therapeutics To Present Results Of Phase 1b Trial For VYN201 At 2024 Global Vitiligo Foundation Annual Scientific Symposium
Benzinga · 02/27 13:14
More
Webull provides a variety of real-time VYNE stock news. You can receive the latest news about Vyne Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYNE
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.